Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Galmed Pharmaceuticals Ltd
GLMDCurrent price
1.38 USD
+0.02 USD (+1.47%)
Last closed
1.24 USD
Company
www.galmedpharma.com
ISIN
IL0011313900
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
3 116 081 USD
Yield for 12 month
-68.42 %
1Y
3Y
5Y
10Y
15Y
GLMD
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel. Address: 16 Abba Hillel Road, Ramat Gan, Israel, 5250608
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
12.00 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
-31 000 USD
Current Quarter
–
Last Quarter
–
Key Figures GLMD
1 year
3 years
5 years
10 years
EBITDA
-6 195 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-22.34 %
PEG Ratio
–
Return On Equity TTM
-49.77 %
Wall Street Target Price
12.00 USD
Revenue TTM
–
Book Value
9.81 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-8.08 USD
Diluted Eps TTM
-8.08 USD
Most Recent Quarter
I 2025
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics GLMD
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History GLMD
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:12
Payout Ratio
–
Last Split Date
30.08.2024
Stock Valuation GLMD
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
0.32
Price Book MRQ
0.19
Financials GLMD
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators GLMD
For 52 weeks
1.21 USD
15.10 USD
50 Day MA
1.97 USD
Shares Short Prior Month
48 498
200 Day MA
3.29 USD
Short Ratio
0.030
Shares Short
68 161
Short Percent
3.11 %
BeatStart